{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:41:33Z","timestamp":1740163293023,"version":"3.37.3"},"reference-count":36,"publisher":"BMJ","issue":"3","funder":[{"name":"Perpetual Foundation","award":["FR2014_0337"],"award-info":[{"award-number":["FR2014_0337"]}]},{"name":"Cancer Australia Priority-Driven Collaborative","award":["APP1098932"],"award-info":[{"award-number":["APP1098932"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Symptoms of raised intracranial pressure (ICP) in recurrent high-grade glioma (HGG) generally require corticosteroid treatment, often causing toxicity with variable effects on ICP symptoms. Acetazolamide reduces ICP when used in other clinical non-cancer settings. The aim of the study was to explore whether the addition of oral acetazolamide enables safe dexamethasone dose reduction in management of raised ICP in recurrent HGG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants had recurrent HGG with any of dexamethasone recommencement, dose increase or dependency; prior\/current bevacizumab was an exclusion. Eligible participants were randomised 1:1 to acetazolamide or placebo for 8\u2009weeks. Standardised protocols were used for dexamethasone dosing, with planned dose decrease from day 5 once ICP symptoms were stable. The primary endpoint was a composite of dexamethasone dose reduction and stable Karnofsky Performance Status Secondary endpoints included toxicity and feasibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty participants (15 per group) were enrolled (mean age 58 years) from seven Australian sites. The mean baseline dexamethasone dose was 6.2\u2009mg. Mean duration on study treatment was 38 days (placebo group) and 31 days (acetazolamide group) with nine participants (30%) completing all study treatments (six placebo, three acetazolamide). Study withdrawal was due to adverse events (n=6; one placebo, five acetazolamide) and disease progression (n=6 (three per arm)). Four participants (13%) (two per arm) were stable responders. Ten participants experienced a total of 13 serious adverse events (acetazolamide arm: five participants (33%), six events, two related).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study closed early due to poor accrual and increasing availability of bevacizumab. The addition of acetazolamide did not facilitate dexamethasone reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ACTRN12615001072505.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2022-004119","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T18:21:34Z","timestamp":1676658094000},"page":"354-362","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and\/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study"],"prefix":"10.1136","volume":"13","author":[{"given":"Meera R","family":"Agar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J","family":"Hovey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth H","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Simes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janette L","family":"Vardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen R","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-5591","authenticated-orcid":false,"given":"Benjamin Y","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merryn","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evonne","family":"Tim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desma","family":"Spyridopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Wen","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarnie","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Jennens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecelia","family":"Gzell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng-Siew","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"2024051713170020000_13.3.354.1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab200"},{"key":"2024051713170020000_13.3.354.2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(03)00410-1","article-title":"Medical decompressive therapy for primary and metastatic intracranial tumours","volume":"2","author":"Sarin","year":"2003","journal-title":"Lancet Neurol"},{"key":"2024051713170020000_13.3.354.3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11060-019-03238-4","article-title":"Evidence-Based dexamethasone dosing in malignant brain tumors: what do we really know?","volume":"144","author":"Jessurun","year":"2019","journal-title":"J Neurooncol"},{"key":"2024051713170020000_13.3.354.4","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1769"},{"key":"2024051713170020000_13.3.354.5","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e3181fa775b"},{"key":"2024051713170020000_13.3.354.6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005072-196607000-00003","article-title":"The ultrastructure of human cerebral edema","volume":"25","author":"Long","year":"1966","journal-title":"J Neuropathol Exp Neurol"},{"key":"2024051713170020000_13.3.354.7","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1966.24.5.0843"},{"key":"2024051713170020000_13.3.354.8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.16.5.521","article-title":"The response of human cerebral edema to glucosteroid administration. an electron microscopic study","volume":"16","author":"Long","year":"1966","journal-title":"Neurology"},{"key":"2024051713170020000_13.3.354.9","doi-asserted-by":"publisher","DOI":"10.1007\/s007010170136"},{"key":"2024051713170020000_13.3.354.10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.23.2.121","article-title":"The effect of dexamethasone on brain edema in patients with metastatic brain tumors","volume":"23","author":"Weinstein","year":"1973","journal-title":"Neurology"},{"key":"2024051713170020000_13.3.354.11","doi-asserted-by":"publisher","DOI":"10.1007\/BF02571300"},{"key":"2024051713170020000_13.3.354.12","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309360118"},{"key":"2024051713170020000_13.3.354.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.4.675"},{"key":"2024051713170020000_13.3.354.14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00520-015-2897-0","article-title":"Validating self-report and proxy reports of the dexamethasone symptom questionnaire -chronic for the evaluation of longer-term corticosteroid toxicity","volume":"24","author":"Agar","year":"2016","journal-title":"Support Care Cancer"},{"key":"2024051713170020000_13.3.354.15","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov054"},{"key":"2024051713170020000_13.3.354.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.9455"},{"key":"2024051713170020000_13.3.354.17","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00771-7","article-title":"Optimal management of corticosteroids in patients with intracranial malignancies","volume":"21","author":"Dixit","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2024051713170020000_13.3.354.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.161"},{"key":"2024051713170020000_13.3.354.19","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-0923-6_13"},{"key":"2024051713170020000_13.3.354.20","doi-asserted-by":"publisher","DOI":"10.1086\/342299"},{"key":"2024051713170020000_13.3.354.21","doi-asserted-by":"publisher","DOI":"10.5754\/hge11154"},{"key":"2024051713170020000_13.3.354.22","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059030-00003"},{"key":"2024051713170020000_13.3.354.23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3171\/jns.2002.97.1.0224","article-title":"Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases","volume":"97","author":"Watling","year":"2002","journal-title":"J Neurosurg"},{"key":"2024051713170020000_13.3.354.24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.238"},{"key":"2024051713170020000_13.3.354.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1"},{"key":"2024051713170020000_13.3.354.26","unstructured":"Karnofsky D , Burchenal J . The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C , ed. Evaluation of Chemotherapeutic Agents. Columbia Univ Press: Columbia, 1949: 196."},{"key":"2024051713170020000_13.3.354.27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024051713170020000_13.3.354.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.022"},{"key":"2024051713170020000_13.3.354.29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1177\/0271678X19859847","article-title":"Controversial roles for dexamethasone in glioblastoma-opportunities for novel vascular targeting therapies","volume":"39","author":"Dubinski","year":"2019","journal-title":"J Cereb Blood Flow Metab"},{"key":"2024051713170020000_13.3.354.30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/neuonc\/noz034","article-title":"Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of Sno and ASCO endorsement of the Congress of neurological surgeons guidelines","volume":"21","author":"Chang","year":"2019","journal-title":"Neuro Oncol"},{"key":"2024051713170020000_13.3.354.31","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/cncr.25945","article-title":"Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial","volume":"117","author":"Kirste","year":"2011","journal-title":"Cancer"},{"key":"2024051713170020000_13.3.354.32","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(18)30004-4","article-title":"Working plan for the use of patient-reported outcome measures in adults with brain tumours: a response assessment in neuro-oncology (RANO) initiative","volume":"19","author":"Dirven","year":"2018","journal-title":"Lancet Oncol"},{"key":"2024051713170020000_13.3.354.33","first-page":"417","article-title":"Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the response assessment in neuro-oncology patient-reported outcome (RANO-PRO) initiative","volume":"8","author":"Dirven","year":"2021","journal-title":"Neurooncol Pract"},{"key":"2024051713170020000_13.3.354.34","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0507-6"},{"key":"2024051713170020000_13.3.354.35","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2024051713170020000_13.3.354.36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/07357907.2021.1944178","article-title":"The sledgehammer in precision medicine: dexamethasone and immunotherapeutic treatment of glioma","volume":"40","author":"Upadhyayula","year":"2022","journal-title":"Cancer Invest"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-004119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:54:26Z","timestamp":1715986466000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-004119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,8,18]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/spcare-2022-004119"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-004119","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"type":"print","value":"2045-435X"},{"type":"electronic","value":"2045-4368"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}